{"groups":[{"description":"Participants will receive:\n\n9-ING-41 administered twice per 21-day cycle on Day 1 and Day 4 for up to 1 year. Treatment with 9-ING-41 may continue beyond 1 year in participants with ongoing clinical benefit.\n\nCarboplatin administered once per 21-day cycle on Day 1 for up to 1 year.","id":"FG000","title":"9-ING-41 + Carboplatin (Part I)"},{"description":"Participants will receive:\n\nPembrolizumab 200 mg IV on Day 1 of each 21-day cycle (±3 days) for Cycles 1 and 2 (lead-in therapy).\n\n9-ING-41 administered twice per 21-day cycle on Day 1 and Day 4 for up to 1 year. Treatment with 9-ING-41 may continue beyond 1 year in participants with ongoing clinical benefit.\n\nCarboplatin administered once per 21-day cycle on Day 1 for up to 1 year.","id":"FG001","title":"Pembrolizumab + 9-ING-41 + Carboplatin (Part II)"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"3"}],"type":"Physician Decision"},{"reasons":[{"groupId":"FG000","numSubjects":"9"},{"groupId":"FG001","numSubjects":"11"}],"type":"Progressive Disease"},{"reasons":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"0"}],"type":"Adverse Event"},{"reasons":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"2"}],"type":"Withdrawal by Subject"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"16"},{"groupId":"FG001","numSubjects":"16"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"}],"comment":"Treatment duration is indefinite. All participants are considered \"not completed,\" and reasons for going off treatment are recorded in the \"Reason Not Completed\" field.","type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"16"},{"groupId":"FG001","numSubjects":"16"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"preAssignmentDetails":"Arms are defined by treatment assignment. Adenoid cystic carcinoma (ACC) and non-ACC represent disease subgroups within each treatment arm and were not assigned to separate treatment arms. Therefore, participants are reported according to treatment assignment rather than histologic subtype.","recruitmentDetails":"Participants were enrolled from 9/17/2021 to 4/12/2024."}